<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pathogens-09-00331-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">pathogens-09-00331-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Common and potent antiviral drugs.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drugs</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy Strategy Categories</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanisms of Therapy</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B14-pathogens-09-00331" ref-type="bibr">14</xref>,
     <xref rid="B39-pathogens-09-00331" ref-type="bibr">39</xref>,
     <xref rid="B40-pathogens-09-00331" ref-type="bibr">40</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine phosphate/ hydroxychloroquine</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-malaria
     <break/>anti-viral
     <break/>anti-inflammatory
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increasing endosomal pH, interfering with the glycosylation of cellular receptors of SARS-CoV-2, immunomodulator</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved to be used in an emergency situation, implemented in many treatment protocols</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B41-pathogens-09-00331" ref-type="bibr">41</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral drug (Nucleoside analogue)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interfering with the viral replication</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Investigational antiviral, clinical trials are in progress</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B42-pathogens-09-00331" ref-type="bibr">42</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baricitinib</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rheumatoid arthritis (RA) drug, AP2-associated protein kinase 1 (AAK1) inhibitor</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interfering with viral entry by inhibiting one of the endocytosis regulators</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B43-pathogens-09-00331" ref-type="bibr">43</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">lopinavir/ritonavir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV protease inhibitor</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Could act by inhibiting SARS-CoV-2 protease for proteins cleavage, interfering with virus replication</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B44-pathogens-09-00331" ref-type="bibr">44</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Darunavir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV protease inhibitor</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Could act by inhibiting SARS-CoV-2 protease for proteins cleavage, interfering with virus replication</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B45-pathogens-09-00331" ref-type="bibr">45</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Camostat Mesylate</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transmembrane protease, serine 2 (TMPRSS2) inhibitor</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interfering with viral entry</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Japan approved</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B46-pathogens-09-00331" ref-type="bibr">46</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Favipiravir</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside analog</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds to the viral RdRp and reduce its reproduction</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Investigational</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B47-pathogens-09-00331" ref-type="bibr">47</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cepharanthie, Selamectin, and mefloquine hydrochloride</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-viral
     <break/>Anti-inflammatory activities
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly reduced cytopathic effects of SARS-CoV-2, and decrease the viral load</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Investigational</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B48-pathogens-09-00331" ref-type="bibr">48</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivermectin</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-parasite</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits SARS-CoV-2 replication in vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
